MAPLIGHT THERAPEUTICS ANNOUNCES INITIATION OF PHASE 1 CLINICAL TRIAL FOR ML-007/PAC, UNDER DEVELOPME

Study to evaluate safety and tolerability of extended-release fixed dose combination ML-007/PAC with precision-matched release kinetics in advance of planned ... Read more

Bron:

Lifestyle